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Artery calcification in uremic rats is increased by a
low protein diet and prevented by treatment with
ibandronate
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The present experiments investigate medial artery
calcification in adult rats made uremic by feeding a synthetic
diet containing 0.75% adenine for 4 weeks. Calcification was
assessed by Alizarin red staining of intact aortas, by von
Kossa staining of carotid artery sections, and by calcium and
phosphate incorporated into the thoracic aorta. The major
conclusions are as follows: Lowering the protein content of
the diet from 25 to 2.5% dramatically increases the frequency
and extent of medial artery calcification in uremic rats
without significantly affecting the elevation in serum
creatinine, phosphate, or parathyroid hormone. This
observation suggests that low dietary protein intake could be
a risk factor for medial artery calcification in uremic patients.
Medial artery calcification in uremic rats is prevented by a
dose of ibandronate that inhibits bone resorption. The
observation suggests that bone resorption inhibitors could
prevent artery calcification in uremic patients. Medial artery
calcification in uremic rats correlates with increased serum
bone Gla protein (BGP; osteocalcin), but not with serum
matrix Gla protein or fetuin. This finding indicates that it
could be of interest to examine the relation between serum
BGP and artery calcification in uremic patients. Each of these
conclusions lends support for our hypothesis that medial
artery calcification is linked to bone resorption. Future
investigations of the as yet unknown biochemical basis for
this link will be facilitated by the present discovery that a
synthetic, 2.5% protein diet containing 0.75% adenine
produces consistent and dramatic medial calcification in
adult rats within just 4 weeks.
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Our long-term goal is to understand the mechanisms that
initiate calcification of the elastic lamellae of the artery media
and the mechanisms that inhibit this calcification. In the
course of our investigations, we have become intrigued with
the evidence for an association between increased bone
resorption and increased artery calcification seen in patients
with postmenopausal osteoporosis (see Price et al.1 for
references), in rats treated with toxic doses of vitamin D,2,3
and in the osteoprotegerin-deficient mouse.4 The existence of
this association has led us to propose that medial artery
calcification is linked to bone resorption, and one prediction
of this hypothesis is that inhibitors of bone resorption should
inhibit artery calcification.1 In previous studies, we tested this
prediction using three different types of bone resorption
inhibitors, each with an entirely different mode of action on
the osteoclast: the amino bisphosphonates alendronate and
ibandronate,1,3,5,6 the cytokine osteoprotegerin,6,7 and the V-
Hþ -ATPase inhibitor SB 242784.8 Each bone resorption
inhibitor proved to potently inhibit medial artery calcifica-
tion in both of the rat models tested: rats in which the
calcification-inhibitory activity of matrix Gla protein (MGP)
was removed by treatment with warfarin and rats treated with
high doses of vitamin D. Ibandronate, osteoprotegerin, and
SB 242784 are each highly specific inhibitors of the osteoclast
at the concentrations used in these studies, and have no
known effects on vascular cells. Their ability to potently
inhibit artery calcification, therefore, strongly supports the
hypothesis that medial artery calcification is linked to bone
resorption.
Calcification of the elastic lamellae of the artery media is
common in patients with chronic kidney disease and causes
adverse hemodynamic changes.9 (Increased calcification of
atherosclerotic plaques is also observed in uremic patients.9)
Arterial medial calcification is also a strong prognostic
marker of all-cause and cardiovascular mortality in hemo-
dialysis patients, independent of classical atherogenic fac-
tors.10 A continuing goal of our research has accordingly been
to test the hypothesis that bone resorption inhibitors can
prevent medial artery calcification in chronic kidney disease,
and we have sought for a number of years to develop a rat
model of uremia that causes consistent and extensive
calcification of the artery media. We initially tried different
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permutations of the 5/6 nephrectomy procedure in the rat,
but the serum creatinine elevations achieved by this
procedure were only about threefold above normal, artery
calcification was observed in less than 20% of the animals,
and the calcification was never extensive (personal observa-
tions). We next induced uremia by feeding rats for 4 weeks
with a diet supplemented with 0.75% adenine, a procedure
shown previously to elevate serum creatinine by about
sevenfold and to induce medial artery calcification.11,12
Because it proved difficult to import the natural diet used
in these earlier studies, we developed a synthetic, adenine-
supplemented diet that mimicked the composition of the
natural diet used in these earlier studies. Rats fed for 4 weeks
with this synthetic diet did have the expected increase in
serum creatinine, but artery calcification was detected in only
about 30% of the animals.
We reasoned that consistent artery calcification might
require a longer period of feeding an adenine-rich diet. In an
attempt to reduce the nitrogen excretion load and so enable
rats to thrive on the adenine-rich diet for periods longer than
4 weeks, we designed a diet that contained 2.5% protein
rather than the 25% protein in the original synthetic diet.
Previous studies have shown that rats fed a 2.5% protein diet
can maintain body mass but cannot grow.13,14 In pilot
studies, we found that all rats fed the diet containing 2.5%
protein and 0.75% adenine unexpectedly had extensive
medial calcification within just 4 weeks; longer periods of
feeding this diet were therefore not pursued.
The goal of the present experiments was to further
investigate the effect of protein content on medial artery
calcification in rats fed an adenine-rich diet for 4 weeks, and
to determine the effect of treatment with a bone resorption
inhibitor on this calcification. Arteries were examined for
calcification by Alizarin red staining of the aortas and
associated arteries, by von Kossa staining of carotid artery
sections, and by extraction and quantitative analysis of
calcium and phosphate incorporated into the artery wall.
Serum from these rats was analyzed for typical measures of
uremia as well as for three proteins whose serum levels are
known to be associated with bone metabolism or artery
calcification: bone Gla protein (BGP; osteocalcin), MGP, and
fetuin (called a2-HS glycoprotein in humans). BGP is the
most abundant non-collagenous bone protein and increased
serum BGP levels are a marker for increased bone turnover in
patients with the high bone turnover type of renal
osteodystrophy.15,16 MGP is a calcification inhibitor secreted
by vascular and other cell types and deficiencies in MGP are
associated with medial artery calcification in mice,17 rats,18
and humans.19 There is evidence that increased serum MGP
levels may be a marker for increased medial artery
calcification in rats treated with high doses of vitamin D.3
Fetuin is a major serum inhibitor of apatite mineral
formation,20–22 and there is evidence that decreased serum
fetuin may be a marker for increased artery calcification in
rats treated with high doses of vitamin D6 and in patients
with chronic kidney disease.23–25
RESULTS
Effect of dietary protein content on medial artery
calcification in uremic rats
In order to assess the effect of dietary protein on medial
artery calcification in uremic rats, 13-week-old adult rats
were fed for 4 weeks with a diet that contained 0.75%
adenine and either 25% protein (11 rats) or 2.5% protein (13
rats). Over the course of this 4-week experiment, the rats fed
the 25% protein lost 27.674.9% of their initial weight and
the rats fed the 2.5% protein lost 31.073.1% of their initial
weight; the difference in weight lost between the two
treatment groups was not statistically significant. A similar
weight loss has been seen previously in rats fed a diet
containing 0.75% adenine for 4 weeks.26
The results of this experiment show that the protein
content of the diet has a major impact on artery calcification
in rats fed a 0.75% adenine diet for 4 weeks. Figure 1 shows
Control
25% protein
(8 of 11)
25% protein
(3 of 11)
2.5% protein
(13 of 13)
2.5% protein
+ Ibandronate
(10 of 11)
Figure 1 | Evidence that a 2.5% protein diet exacerbates artery
calcification in uremic rats and that treatment with ibandronate
prevents this calcification: Alizarin red staining of aortas.
Thirteen-week-old adult male rats were fed a synthetic diet
containing 0.75% adenine for 4 weeks in order to induce uremia. The
diet for 11 rats contained 25% protein, whereas the diet for 24 rats
contained 2.5% protein. Eleven animals in the 2.5% protein group
were injected daily with the bone resorption inhibitor ibandronate at
a dose of 0.25 mg/kg (see Materials and Methods). Twelve rats of the
same age served as controls. The figure shows the Alizarin red S
staining of the aorta from a representative animal in each treatment
group, with the aorta oriented so that the femoral bifurcation is on
the right, a carotid artery on the left, and the celiac and mesenteric
arteries on the bottom. Note the complete absence of Alizarin red
staining in the arteries of rats fed the adenine diet with 2.5% protein
and treated daily with ibandronate.
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that all 13 rats fed the 2.5% protein diet had uniform Alizarin
red staining in the aorta and in the associated arteries. In
contrast, only three of the 11 rats fed the 25% protein diet
had evidence of Alizarin red staining for calcification, and in
these rats staining involved no more than half of the artery
wall (Figure 1). Figure 2 shows that the rats fed the 2.5%
protein diet also had consistent von Kossa staining in the
elastic lamellae of the carotid artery media. In contrast, only
the three rats in the 25% protein group that had Alizarin red
staining also had von Kossa staining in the carotid artery
media (not shown). Figure 3 shows that the rats fed the 2.5%
protein diet all have an approximately 1000-fold elevation of
calcium and phosphate in the artery wall compared to age-
matched control rats (Po0.001). In contrast, only the three
rats in the 25% protein group that had Alizarin red staining
had statistically significant elevations of calcium and
phosphate in the artery wall (Figure 3). Taken together,
these data demonstrate that a 2.5% protein diet dramatically
increases the frequency with which artery calcification is
observed in uremic rats compared to the calcification
frequency seen in rats fed the 25% protein diet.
Serum measures of uremia in rats fed a diet containing
adenine and either 2.5 or 25% protein are shown in Table 1.
Both diets produced a comparable increase in serum levels of
phosphate, creatinine, and parathyroid hormone (PTH), and
a comparable decrease in serum albumin. Both diets also
dramatically elevated serum blood urea nitrogen, but the
extent of elevation was greater in the rats fed 25% protein, as
expected. Total and corrected serum calcium levels were
normal in the rats fed the diet containing adenine and 25%
protein, and slightly reduced in the rats fed the diet
containing adenine and 2.5% protein (Pp0.01).
Three serum markers of bone metabolism and/or artery
calcification were measured to determine if any marker
correlated with the extent of artery calcification. As seen in
Table 2, serum BGP correlates with artery calcification in the
uremic rat, with a twofold elevation in the rats fed the 25%
protein diet compared with an eightfold elevation in rats fed
the 2.5% diet. Serum fetuin and MGP levels were both
dramatically affected by uremia and by the protein content of
Control
25% protein
2.5% protein
2.5% protein
+ Ibandronate
Figure 2 | Evidence that a 2.5% protein diet exacerbates artery
calcification in uremic rats and that treatment with ibandronate
prevents this calcification: von Kossa staining of carotid arteries.
In the experiment described in Figure 1, one carotid artery from each
rat was removed immediately after the rats were killed, fixed in
10% buffered formalin, and cross-sections of each artery were stained
for calcification with von Kossa (stains calcification brown to black)
and counter-stained with nuclear fast red. The panels illustrate the
typical level of medial calcification seen in the carotid artery of the
13 uremic animals fed the 2.5% protein diet, and the absence of
calcification in the carotid artery of the 12 control animals, in the
artery of eight of the 11 uremic animals fed a 25% protein diet, and in
the artery of the 11 uremic animals fed the 2.5% protein diet and
treated with ibandronate. The three uremic rats fed the 25% protein
diet whose arteries stained with Alizarin red (Figure 1) also had
von Kossa staining for calcification in the carotid artery (not shown).
The arrows indicate sites of calcification of the elastic lamellae in
the uremic rats fed the 2.5% protein diet.
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Figure 3 | Evidence that a 2.5% protein diet exacerbates artery
calcification in uremic rats and that treatment with ibandronate
prevents this calcification: calcium and phosphate levels in
thoracic aortas. A 4 cm segment of the thoracic aorta from each
animal in the experiment described in Figure 1 was analyzed for
calcium and phosphate (see Materials and Methods). Each point in
the figure shows the level of calcium or phosphate found in a single
thoracic segment. Closed symbols (K) denote values obtained
from thoracic aortas that stained with Alizarin red; open symbols
(J) denote values obtained from thoracic aortas that did not stain.
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the diet, but these changes did not correlate with the extent of
artery calcification.
To further evaluate the possible association between serum
BGP and artery calcification in uremic rats, serum BGP levels
in each of the 13 rats fed adenine and 2.5% protein were
plotted against the calcium level found in the thoracic aorta
of the same rat. As can be seen in Figure 4, there is a strong
positive correlation between serum BGP levels measured at
the time of death and the level of calcium in the artery wall
(r¼ 0.81; Po0.001). A strong, positive correlation was also
found between serum BGP and the level of phosphate in the
artery wall (not shown).
Effect of ibandronate treatment on medial artery calcification
in uremic rats
In order to assess the effect of inhibiting bone resorption on
medial artery calcification in uremic rats, 11 rats were fed for
4 weeks with a diet that contained 2.5% protein and 0.75%
adenine and treated daily with ibandronate at a dose
previously shown to inhibit bone resorption and prevent
artery calcification in other rat models.1,3,5,6 As noted above,
all rats in the group that did not receive ibandronate had
extensive Alizarin red and von Kossa staining for calcification
(Figures 1 and 2) and a dramatic, 1000-fold increase in
calcium and phosphate in the artery wall (Figure 3). In
contrast, 10 of the 11 rats treated with ibandronate had no
evidence of Alizarin red staining for calcification (Figure 1),
while one rat had a small region of Alizarin red staining in
the thoracic aorta (not shown). None of the 11 rats treated
with ibandronate had evidence of von Kossa staining in
carotid artery sections (Figure 2), and all of the rats treated
with ibandronate had a 100- to 1000-fold reduction in
calcium and phosphate in the artery wall compared to uremic
rats that were not treated with ibandronate (Figure 3). These
data show that ibandronate treatment prevents medial artery
calcification in 10 of 11 rats, and dramatically reduces
calcification in one rat.
The effect of ibandronate treatment on serum measures of
uremia are shown in Table 1. Ibandronate treatment did not
significantly affect the increase in serum levels of phosphate,
creatinine, blood urea nitrogen, or PTH in the uremic rat.
Ibandronate treatment did, however, reduce serum calcium
Table 1 | Serum biochemical measurements
Serum measurement Control (n=12) 25% Protein (n=11) 2.5% Protein (n=13) 2.5% Protein+ibandronate (n=11)
Calcium (mM) 2.670.1 2.470.2a 2.070.3b,c 1.770.2b,c,d
Albumin (g/dl) 3.970.3 3.570.3b 3.270.4b 3.470.3b
Total protein (g/dl) 5.970.5 5.670.5 5.070.7b,e 5.370.6f
Corrected Ca (mM) 2.670.2 2.570.2 2.270.2b,c 1.970.2b,c,g
Phosphate (mM) 2.570.2 4.870.8b 5.671.1b 5.871.1b,e
Creatinine (mg/dl) 0.470.1 3.770.8b 4.270.8b 4.170.7b
BUN (mg/dl) 9.475.5 187.8723.8b 130.7740.5b,c 105.1735.4b,c
PTH (pg/ml) 64.7711.6 1777.07667.9b 2218.27267.1b 2554.871054.0b
BUN, blood urea nitrogen; PTH, parathyroid hormone.
Blood was obtained from rats in each of the four indicated treatment groups 4 weeks after rats had been placed on to an adenine-containing diet in order to induce uremia
(see Figure 1). Blood was allowed to clot for 30 min at room temperature; serum was obtained by centrifugation, and stored at 701C until analyzed. The values presented are
the mean 7s.d. For the measurement of PTH, n=6 for the control group, n=5 for the 25% protein group, n=6 for the 2.5% protein group, and n=5 for the 2.5%
protein+ibandronate group. Corrected calcium is calcium normalized for differences in serum albumin.27,28
aPo0.01 compared to value for control.
bPo0.001 compared to value for control.
cPo0.001 compared to value for 25% protein.
dPo0.01 compared to value for 2.5% protein.
ePo0.05 compared to value for 25% protein.
fPo0.025 compared to value for control.
gPo0.001 compared to value for 2.5% protein.
Table 2 | Levels of calcium and phosphate in thoracic aorta segments and serum levels of bone-associated proteins
Measurement Control (n=12) 25% Protein (n=11) 2.5% Protein (n=13) 2.5% Protein+ibandronate (n=11)
Thoracic aorta Ca (mmol) 0.0770.02 4.83710.16 80.59753.69a,b 0.1770.09a,c
Thoracic aorta PO4 (mmol) 0.0270.01 2.7975.96 49.99734.24
a,b 0.0470.02c,d
Serum BGP (ng/ml) 185.6744.8 530.97281.9a 1620.27993.9a,b 266.67130.5c,e
Serum MGP (ng/ml) 198.8725.4 1216.07185.2a 926.47120.7a,b 1882.67404.3a,b,c
Serum fetuin (mg/ml) 0.8970.06 0.1470.06a 0.3870.07a,b 0.1270.05a,c
BGP, bone Gla protein; MGP, matrix Gla protein.
Blood was obtained from rats in each of the four indicated treatment groups 4 weeks after rats had been placed on to an adenine-containing diet in order to induce uremia
(see Figure 1). Blood was allowed to clot for 30 min at room temperature; serum was obtained by centrifugation, diluted into RIA diluent, and stored at 701C until analyzed.
The values presented are the mean7s.d. For the measurement of fetuin, n=6 for the control group, n=5 for the 25% protein group, n=6 for the 2.5% protein group, and n=5
for the 2.5%+ibandronate group. For the measurement of serum MGP, n=6 for the control group.
aPo0.001 compared to value for control.
bPo0.001 compared to value for 25% protein.
cPo0.001 compared to value for 2.5% protein.
dPo0.01 compared to value for control.
ePo0.025 compared to value for 25% protein.
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by about 15% (Pp0.01). The effect of ibandronate treatment
on three serum markers of bone metabolism and/or artery
calcification were measured to determine if any marker
correlated with the extent of artery calcification. As seen in
Table 2, only serum BGP levels correlate with artery
calcification in rats treated with ibandronate.
DISCUSSION
The data presented here support three conclusions concern-
ing medial artery calcification in the adenine-fed rat model of
end-stage renal disease: (1) Lowering the protein content of
the diet from 25 to 2.5% dramatically increases the frequency
and extent of medial artery calcification in uremic rats
without significantly affecting the elevation in serum
creatinine, phosphate, or PTH. (2) Medial artery calcification
in rats fed adenine and a 2.5% protein diet is prevented by a
dose of ibandronate that has been previously shown to
inhibit bone resorption and medial artery calcification in two
other rat artery calcification models.1,3,5,6 (3) Elevated serum
levels of BGP, a marker for bone turnover in uremic
patients,15,16 are strongly correlated with medial artery
calcification in rats fed adenine and a 2.5% protein diet.
Each of these three conclusions supports the hypothesis
that there is a relationship between bone resorption and
medial artery calcification in end-stage renal disease. (1) Low
dietary protein has been demonstrated to increase bone
resorption, leading to progressive loss of bone and augment-
ing bone loss in osteoporosis.29 Low dietary protein would
therefore be expected to augment the increase in bone
resorption caused by elevated serum PTH in the uremic rat.11
The fact that low dietary protein dramatically increases artery
calcification therefore supports the existence of a link
between bone resorption and medial artery calcification.
(2) Amino bisphosphonates such as ibandronate bind to
bone mineral, are taken up by the osteoclast during the
process of bone resorption, and specifically inhibit farnesyl
diphosphate synthase in the osteoclast, thereby inhibiting the
bone resorption activity of the cell. The dose of ibandronate
used in this study has been shown to inhibit bone resorption
in the rat,1,3,5 and there is also evidence that ibandronate
treatment prevents hyperparathyroid bone changes in rats
with mild renal failure.30 The ability of ibandronate to
prevent medial artery calcification in the uremic rat therefore
supports a link between bone resorption and medial artery
calcification. (Because of the low ibandronate doses used in
these studies, it is unlikely that ibandronate prevents artery
calcification by directly inhibiting mineralization (see Price
et al.1 and references therein), as pyrophosphate and
etidronate are known to do. The ultimate test of mechanism
will be to verify that other agents that inhibit bone
resorption, such as osteoprotegerin, are also able to inhibit
artery calcification in the uremic rat.) (3) Elevated serum
BGP has been shown to correlate with increased bone
turnover in patients with end-stage renal disease.15,16 We
believe that the elevation in serum BGP observed in the
adenine-fed, uremic rat likewise arises from increased bone
turnover, and that ibandronate treatment lowers serum BGP
by inactivating osteoclastic bone resorption and thereby
inhibiting bone turnover. It should be noted that the present
study did not evaluate the effects of a low protein diet or of
ibandronate on bone resorption, and that future studies will
be needed to confirm that the predicted effects of these
treatments on bone metabolism are actually observed in rats
with adenine-induced uremia.
Our working hypothesis is that the impetus for medial
artery calcification in the uremic rat begins with the
elevation in serum phosphate. Genetic studies in mice have
shown that increases in serum phosphate are associated with
ectopic calcification in mice lacking MGP or Ank genes,31
and our recent studies of the serum calcification factor that
initiates the calcification of the elastic lamellae in devitalized
arteries demonstrates that serum phosphate has a direct,
biochemical effect on the ability of the serum calcification
factor to initiate ectopic mineralization.32 Elevated serum
phosphate also elevates serum PTH in the uremic rat, and
elevated serum PTH in turn accelerates bone resorption.
In our view, this PTH-stimulated increase in bone resorp-
tion is a major driver of medial arterial calcification in the
uremic rat.
The biochemical mechanism for the putative linkage
between increased bone resorption and increased medial
artery calcification in uremia is presently unclear. It is
possible that an agent (or agents) responsible for calcification
of the elastic lamellae of the artery media arises from sites of
bone turnover, travels in blood, and initiates calcification
within the artery media. This agent could directly initiate
calcification in the artery, a hypothesis supported by the
recent discovery that serum contains a macromolecular
causative agent that initiates the calcification of the elastic
lamellae of devitalized arteries.32 Alternatively, this agent
could be a signaling molecule that arises from sites of bone
turnover, travels in blood, and initiates medial artery
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Figure 4 | Correlation between thoracic aorta calcium levels and
serum BGP levels in uremic rats. Serum samples obtained from
each of the 13 uremic rats that were fed the 2.5% protein diet but
were not treated with ibandronate (see Figure 1) were assayed for
BGP by radioimmunoassay (see Materials and Methods). Serum BGP is
plotted against the calcium level found in the thoracic aorta of the
same rat.
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calcification by virtue of a direct action on vascular smooth
muscle cells in the artery wall.33–35 These and other possible
explanations for the apparent linkage between bone resorp-
tion and medial artery calcification in rats fed the adenine-
rich, low protein diet merit future study. Many of these future
investigations of medial artery calcification in the rat model
of end-stage renal disease will be facilitated by the present
discovery that a synthetic, 2.5% protein diet containing
0.75% adenine produces consistent and dramatic medial
calcification in adult rats within 4 weeks.
Each of the three conclusions of this animal study have
potential implications for the clinical management of uremic
patients: (1) Low dietary protein intake could be a risk factor
for medial artery calcification in the uremic patient. (2)
Treatment with a bone resorption inhibitor such as the
amino bisphosphonate ibandronate could prevent medial
artery calcification in uremic patients. (It should be noted,
however, that treatment of uremic patients with a closely
related amino bisphosphonate, pamidronate, is associated
with the development of adynamic bone disease,36 and that
there is a recent report that adynamic bone disease is
associated with increased arterial calcification in uremic
patients.37) (3) Increased serum levels of BGP, but not MGP
or fetuin, may correlate with the initiation of medial artery
calcification in the uremic patient, and reduction in serum
BGP could provide a marker for monitoring treatment of
uremic patients with ibandronate.
MATERIALS AND METHODS
Materials
Ibandronate (Bondronat, Boehringer Mannheim, Germany) was
purchased from Idis World Medicines (Surrey, UK); an ibandronate
solution was prepared with 0.15 M NaCl and stored at 41C. Adenine
(Acros Organics, Geel, Belgium) was purchased from Fisher
Scientific (Hampton, NH, USA). Four different isocaloric synthetic
diets (350 kcal/100 g) were purchased from Harlan Teklad (Madison,
WI, USA), each containing 4.7% fat, 5% cellulose, 1.06% calcium,
and 0.92% phosphorus. One diet contained 2.5% protein (casein)
and 75.3% carbohydrate (TD05030); a second contained 2.5%
protein, 74.6% carbohydrate, and 0.75% adenine (TD05031); a third
contained 50.3% carbohydrate and 25.4% protein (casein)
(TD04512); and a fourth contained 49.6% carbohydrate, 25.4%
protein, and 0.75% adenine (TD04513). Thirteen-week-old male
rats (Sprague–Dawley derived) were purchased from Harlan
Sprague–Dawley (San Diego, CA, USA).
Treatment of rats
Rats were fed the diets containing 0.75% adenine and either 2.5 or
25% protein for 4 weeks ad libitum. In order to assess the effect of
ibandronate on vascular calcification, a subset of the rats fed the
2.5% protein diet received once daily subcutaneous injections of
ibandronate at a dose of 0.25 mg/kg body weight/day. Ibandronate
injections began 12 days after the start of the adenine diet, a time at
which there was no detectable vascular calcification (personal
observations). The average initial weight of the adenine-fed rats was
371.478.4 g, and the weight loss over the 4-week experiment was:
27.674.9% (adenine/25% protein); 31.073.1% (adenine/2.5%
protein); and 29.673.7% (adenine/2.5% protein/ibandronate).
Animals were killed by exsanguination while under ether
anesthetic and blood was allowed to clot for 30 min at room
temperature. Serum was collected by centrifugation at 1400 g for
10 min. An aliquot of serum was immediately diluted into radio-
immunoassay diluent38 and stored at 701C until analysis of BGP,
MGP, and fetuin by radioimmunoassay. The remaining serum was
stored in 0.5 ml aliquots at 701C until use. The UCSD Animal
Subjects Committee approved all animal experiments.
Methods
The right carotid artery, the thoracic and abdominal aortas, and
portions of the pulmonary, mesenteric, hepatic, renal, celiac, and
femoral arteries from each rat were dissected as a unit within 30 min
of the animal’s death, stained with 0.0016% (wt:vol) Alizarin red S
in 0.5% KOH for 24 h, destained in 0.05% KOH, and photographed.
For histological analyses, the left carotid artery was fixed in 10%
buffered formalin for at least 1 day at room temperature, and San
Diego Pathologists (San Diego, CA, USA), sectioned and von Kossa
stained the artery. For quantitative assessment of calcification, a
4 cm segment of each thoracic aorta (beginning at the aortic arch
and moving distally) was patted dry with a paper towel, placed in a
5 ml tube, and extracted by end-over-end mixing with 2 ml of 0.15 M
HCl for 24 h at room temperature. Calcium levels in serum and
in the acid extracts of tissues were determined colorimetrically
using cresolphthalein complexone (JAS Diagnostics, Miami FL,
USA) and phosphate levels were determined colorimetrically as
described.39
Serum creatinine and blood urea nitrogen values were deter-
mined by the clinical laboratory at the UCSD Medical Center using
a Beckman-Coulter LX-20 PRO serum/plasma blood analyzer.
Serum albumin and total protein were determined by the
Comparative Pathology Lab at UC Davis using a COBAS MIRA
Plus analyzer (Roche Diagnostic Systems, Indianapolis, IN, USA).
Serum samples were analyzed to determine the levels of BGP, MGP,
and fetuin using specific radioimmunoassays developed in our
laboratory.38,40,41 Serum levels of PTH were determined using a rat
intact PTH enzyme-linked immuno sorbent assay (ELISA) assay
(Immutopics, San Clemente, CA, USA).
Statistical analysis
All quantitative data are presented as mean7s.d. Differences
between groups were analyzed by the Student’s t-test. Differences
with Po0.05 were accepted as significant.
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